ATM was originally identified by positional cloning as the gene that underlies the autosomal recessive condition ataxia-telangiectasia. The encoded protein plays a central role in the complex processes that repair DNA doublestrand breaks. Nearly 20 years ago, epidemiological surveys of relatives of ataxia-telangiectasia cases suggested that female relatives were at modestly increased risk of breast cancer. Subsequently, many studies have tried to clarify the role of ATM in breast cancer susceptibility, but have produced inconclusive and/or inconsistent results. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.
Ataxia-telangiectasia
Ataxia-telangiectasia (MIM 208900) is an autosomal recessive condition with an estimated frequency of 1 in 40 000 to 1 in 300 000 in Caucasian populations . It is characterized by progressive cerebellar ataxia, oculomotor apraxia, frequent infections, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, sensitivity to ionizing radiation and an increased risk of malignancy (Chun and Gatti, 2004; Taylor and Byrd, 2005) . Individuals with ataxiatelangiectasia are estimated to have a 100-fold increased risk of cancer compared with the general population. Lymphoid cancers predominate in childhood, and epithelial cancers, including breast cancer, are seen in adults .
The gene for ataxia-telangiectasia was mapped to chromosome 11q by genetic linkage analysis in 1988 and was identified by positional cloning in 1995 (Gatti et al., 1988; Savitsky et al., 1995) . The gene was called ATM (ataxia-telangiectasia mutated). Although the condition was initially thought to be genetically heterogeneous and had been delineated into four complementation groups, ATM mutation analysis revealed that all groups were due to mutations in the same gene (Savitsky et al., 1995) .
The majority of ataxia-telangiectasia patients are compound heterozygotes or homozygotes for identifiable ATM mutations that have been inherited from each parent. The prevalence of such ATM mutations has been shown to be 0.5-1% in Western populations Renwick et al., 2006) . Over 300 distinct mutations have been reported (see www.benaroyaresearch. org) of which >80% are base substitutions or insertions/deletions that generate premature termination codons or splicing abnormalities. The truncated species is usually unstable and results in absent or severely reduced protein expression. Certain missense mutations can also cause ataxia-telangiectasia, but only account for approximately 10% of ATM mutations identified in ataxia-telangiectasia patients. Base substitutions in ATM are common and it can, therefore, be difficult to deduce whether a specific missense mutation is causative of ataxia-telangiectasia, particularly if protein expression is not abnormal.
ATM structure and function
The ATM gene is located at 11q22.3 and consists of 66 exons, 62 of which encode a protein of 3056 amino acids (Savitsky et al., 1995) . ATM belongs to a protein family known as the PI3K-related protein kinases (PIKK) (Abraham, 2004) . These proteins are characterized by a domain similar to that in phosphatidylinositol 3-kinase and most PIKKs, including ATM, are active serine/ threonine kinases. ATM also contains a C-terminal FAT domain (FRAP, ATM, TRAPP), with a highly conserved 35 residue tail known as the FATC domain (Bosotti et al., 2000) . This domain appears to be important for regulating the kinase activity of ATM and for binding regulatory proteins (Jiang et al., 2006) . The N-terminus of ATM includes several HEAT domains that may influence interactions with other proteins (Perry and Kleckner, 2003) and a region essential for substrate binding (Fernandes et al., 2005) . Other putative motifs, including an incomplete leucine zipper and a proline-rich region that binds c-Abl, have been reported, but are less well characterized (Lavin et al., 2004) .
ATM has multiple complex functions including a central role in the repair of DNA double-strand breaks. The response to DNA damage includes numerous processes including recognition of damaged DNA, recruitment of repair proteins, signalling to cell cycle checkpoints, transcriptional regulation and activation of apoptosis. ATM is involved in many of these processes. In normal cells ATM exists as inert dimers or multimers. In response to double-strand DNA breaks ATM dissociates to highly active monomers (Bakkenist and Kastan, 2003) . During this process, ATM undergoes autophosphorylation on Ser1981 and is recruited to sites of DNA damage where it initiates a signalling cascade through phosphorylation of multiple DNA damage response and cell-cycle proteins, including proteins encoded by breast cancer susceptibility genes such as TP53, BRCA1 and CHEK2. Full exposition of the functions of ATM is beyond the scope of this article and the reader is referred to recent reviews (Kurz and LeesMiller, 2004; Jeggo and Lobrich, 2006; Shiloh, 2006) .
Epidemiological evidence for breast cancer risk in ATM heterozygotes
Swift first proposed that relatives of ataxia-telangiectasia might be at increased risk of breast cancer nearly twenty years ago (Swift et al., 1987) . His analysis of cancer incidence in 110 ataxia-telangiectasia families suggested that the relative risk of cancer was 2.3 for men and 3.1 for women, with breast cancer being the most strongly associated cancer. This observation was clearly of importance to ataxia-telangiectasia families, but also had potential wider significance given that it was estimated that up to 1% of the population might be carriers of an ataxia-telangiectasia predisposing mutation. Thus, even a relatively modest increase in breast cancer risk in carriers could equate to an appreciable population attributable risk.
Subsequent to Swift's initial report, several epidemiological surveys of cancer incidence in relatives of ataxiatelangiectasia cases were conducted and confirmed the increased risk of breast cancer. A review of four of these studies estimated the breast cancer relative risk to be 3.9 (Easton, 1994) . Recently, a large study of 1160 relatives of 169 ataxia-telangiectasia patients was published (Thompson et al., 2005b) . This comprehensive analysis estimated the overall relative risk of breast cancer in carriers to be 2.23 (95% CI ¼ 1.16-4.28) compared to the general population and was higher in women under 50 years of age at 4.9 (95% CI ¼ 1.90-12.9).
Molecular evidence for breast cancer risk in ATM heterozygotes
A key prediction of the observation that relatives of ataxia-telangiectasia cases are at increased risk of breast cancer is that ATM mutations should occur at increased frequency in breast cancer cases compared with controls. However, the first analysis of 401 breast cancer cases and 201 controls for ATM mutations did not support this (FitzGerald et al., 1997).
A variety of reasons were suggested to explain the apparent contradiction between the epidemiological studies and this initial case-control comparison of ATM in breast cancer. The model put forward by Gatti et al. (1999) has been most widely embraced and proposed that the ATM mutations that confer susceptibility to breast cancer differ from those that occur in ataxia-telangiectasia. Specifically, they proposed that missense ATM variants might differ from truncating ATM mutations in their effect on ATM activity and hence cancer susceptibility. They predicted that carriers of ATM truncations would have 50% of wild-type ATM activity and a normal phenotype. Individuals with two truncations would have essentially no ATM protein and would have ataxia-telangiectasia. By contrast, they postulated that certain ATM missense variants might encode functionally abnormal proteins that could act in a dominant-negative fashion, which would therefore have more substantial effects on ATM function than a single truncating mutation. This could result in distinct phenotypic consequences in carriers of ATM missense variants, such as cancer susceptibility. However, individuals with two missense variants would not have sufficient abrogation of ATM activity to result in ataxia-telangiectasia (Gatti et al., 1999) . Although this model can explain the apparent absence of enrichment of ATM truncating mutations in individuals with breast cancer, it does not easily explain the increased risk of breast cancer in female relatives of ataxia-telangiectasia cases.
Over the last decade numerous studies have been performed to try to clarify the role of ATM in breast cancer susceptibility (Table 1 ). The majority of these studies have been inconclusive primarily due to two constraining factors. First, most have included small numbers of cases, partly because ATM is large and arduous to screen. Second, very few studies have screened the whole ATM gene in both cases and controls, thereby limiting the ability to directly compare the frequency and type of identified sequence variants. This is particularly important with respect to missense variants, which are common throughout the genome. For variants of appreciable prevalence, a comparison of the frequency of the specific variant in cases and controls can be undertaken. However, for rare missense variants, the absence of the specific variant in controls confirms that it is rare but gives very little information about the potential role of the variant in cancer susceptibility. Demonstration of an effect on ATM function is supportive that the variant might be associated with a given phenotype, but does not in itself prove that the variant confers susceptibility to breast cancer.
To clarify the role of ATM in breast cancer susceptibility we recently conducted an analysis that attempted to overcome these difficulties (Renwick et al., 2006) . We adopted a familial case vs control design using 443 BRCA1/2 negative familial breast cancer cases and 521 controls. This design gives an approximately fourfold increase in power over unselected breast cancer cases. We also screened the full gene in all cases and all controls so that the frequency and spectrum of mutations could be evaluated in a direct, unbiased analysis.
We identified two ATM mutations that cause ataxiatelangiectasia in controls and 12 in familial breast cancer cases (P ¼ 0.0043). These mutations included truncations, splice-site abnormalities and two missense mutations that were known to affect protein function and to cause ataxia-telangiectasia (Renwick et al., 2006) . These results are fully consistent with epidemiological studies that predict that ATM mutations that cause ataxia telangiectasia should occur at increased frequency in breast cancer.
As both cases and controls were fully screened through the gene, a direct comparison of the frequency and type of missense mutations in cases and controls could be undertaken. We identified 37 nonsynonymous missense variants of which 12 were present in both cases and controls, 15 were present exclusively in cases and 10 were present exclusively in controls. For commoner missense variants such as S49C, F858L, P1054R, L1420F and D1853N there was no difference in variant frequency in cases and controls, consistent with most of the previous studies that have examined these variants (Table 1 ). Of the rare missense mutations, two were previously known to cause ataxia-telangiectasia, T7271G (V2424G) and SV2855_2856RI, and these were only present in cases. Of note, there was no significant difference in the frequency of nonsynonymous missense variants that occurred either exclusively in cases or exclusively in controls. Neither was there any significant difference in the predicted pathogenicity or position with respect to functional domains of these variants in cases and controls. These data highlight the difficulty in deducing the phenotypic consequences of sequence changes that do not result in protein truncation. Undoubtedly certain nonsynonymous missense variants can cause ataxia-telangiectasia and it is anticipated that such variants also confer susceptibility to breast cancer. The effects of other missense variants, not already known to be associated with ataxia-telangiectasia, are more difficult to predict, but our data suggest that the majority are not associated with increased risks of breast cancer (Renwick et al., 2006) .
The relative risk of breast cancer associated with ATM mutations was estimated to be 2.37 (95% CI ¼ 1.51-3.78, P ¼ 0.0003) by segregation analysis incorporating information from the controls and the full pedigrees of the cases. This is very similar to the risks estimated from epidemiological analyses (Thompson et al., 2005b) . Therefore, the recent large epidemiological and molecular analyses of ATM have provided entirely consistent data that indicate that ATM mutations that cause ataxia-telangiectasia are low penetrance breast cancer susceptibility alleles conferring B2-fold Shayeghi et al. (1998) ATM screened in 41 breast cancer cases that developed tissue reactions post-radiotherapy and in 39 controls Bay et al. (1998) ATM screened in 18 breast cancer cases from families with breast and gastric cancer Chen et al. (1998) ATM screened in 100 familial breast cancer cases Izatt et al. (1999) ATM screened in 100 breast cancer cases o40 years. 106 controls screened for variants found in cases Drumea et al. (2000) ATM screened in 37 breast cancer cases Broeks et al. (2000) ATM screened in 82 breast cancer cases o45 years. 268 controls screened for IVS10-6T>G Shafman et al. (2000) ATM screened in 57 bilateral breast cancer cases Laake et al. (2000) 483 breast cancer cases screened for 6 ATM variants Teraoka et al. (2001) ATM screened in 177 breast cancer cases and 81 controls Dork et al. (2001) ATM screened in 192 breast cancer cases. 1000 controls screened for variants found in cases Iannuzzi et al. (2002) ATM screened in 46 breast cancer cases Sommer et al. (2002) ATM screened in 43 breast cancer cases and 43 controls Maillet et al.(2002) ATM screened in 94 breast cancer cases diagnosed o40 years. 140 controls screened for variants found in case Offit et al. (2002) ATM screened in 37 cases with Hodgkin's disease, 10 of whom also had breast cancer. 128 controls screened for variants found in cases Allinen et al. (2002) 215 familial breast cancer cases, 85 nonfamilial breast cancer cases and 200 controls screened for eight ATM mutations Chenevix-Trench et al. (2002) 525 or 262 breast cancer cases and 381 or 68 controls screened for T7271G and IVS10-6T>G, respectively Spurdle et al. (2002) 1300 breast cancer cases and 600 controls screened for T2119C and C3161G Bernstein et al. (2003) 1149 breast cancer cases screened for T7271G and IVS10-6T>G Thorstenson et al. (2003) ATM screened in approximately 270 individuals with a family history of breast and/or ovarian cancer, 60% of whom had breast cancer and 52 controls. Additional controls screened for L1420F and/or IVS10-6T>G Sommer et al. (2003) ATM screened in 47 breast cancer cases and 47 controls Angele et al. (2003) ATM screened in 51 breast cancer cases. 203 breast cancer cases screened for 16 specific variants Bretsky et al. (2003) 428 breast cancer cases and 428 controls screened for 20 variants Szabo et al. (2004) 961 familial breast cancer cases screened for T7271G and IVS10-6T>G Lindeman et al. (2004) 496 breast and/or ovarian cancer cases screened for IVS10-6T>G Buchholz et al. (2004) ATM screened in 67 breast cancer cases. 940 controls screened for variants found in cases Tamimi et al. (2004) 1309 breast cancer cases and 1761 controls screened for five ATM haplotypes Thompson et al. (2005a) 378 or 373 familial breast cancer cases and 775 or 84 controls screened for IVS10-6T>G and L1420F, respectively Lee et al. (2005) 996 breast cancer cases and 1181 controls screened for ive variants Renwick et al. (2006) ATM screened in 443 familial breast cancer cases and 521 controls ATM and breast cancer susceptibility M Ahmed and N Rahman risks of breast cancer (Thompson et al., 2005b; Renwick et al., 2006) . Moreover, the analyses demonstrate that, in the UK population, the combined ATM mutation prevalence is similar to that of CHEK2*1100delC, and that ATM mutations are associated with similar risks of breast cancer and make a similar contribution to breast cancer incidence as CHEK2*1100delC (Renwick et al., 2006; Nevanlinna and Bartek, 2006, this issue) .
Future challenges
Although substantial progress has been made in our understanding of the role of ATM in breast cancer susceptibility there are several questions that need further investigation, such as the identification of factors that determine breast cancer occurrence in ATM mutation carriers, risks of other cancers, whether ATM heterozygotes are more sensitive to radiation and the clinical utility/implementation of ATM mutation testing.
Age and mutation specific risks Overall, all ATM mutations together confer a B2-fold risk of breast cancer (Thompson et al., 2005b; Renwick et al., 2006) . However, there are indications that factors such as age and the specific mutation may influence breast cancer risk. Epidemiological analyses suggest that the risk of breast cancer in ATM carriers is higher in women under 50 years and may be higher in first-degree relatives of ataxia-telangiectasia cases compared to more distantly related ATM heterozygotes (Olson et al., 2005; Thompson et al., 2005b) . The breast cancer risk in individuals above and below 50 years was not significantly different in the study by Renwick et al. (2006) but there was limited power to investigate the age-specific risks of ATM mutations. Nevertheless, the estimate was consistent with the higher risks in younger individuals reported in epidemiological studies. The age-specific risks associated with ATM mutations will need further investigation. Another question that needs further research is whether there are mutation-specific differences in cancer risk. One particular mutation, T7271G, has been proposed to have a higher risk of breast cancer (Stankovic et al., 1998) . This mutation was originally identified in two families with a mild form of ataxiatelangiectasia associated with slowly progressing ataxia, minimal telangiectasia and fertility and is associated with low levels of kinase activity (Stankovic et al., 1998; Stewart et al., 2001) . In the first of the families, two individuals homozygous for T7271G developed breast cancer at 44 and 50 years and their mother, an obligate carrier of the mutation, developed breast cancer at 82 years. In the second family, two brothers with ataxiatelangiectasia were compound heterozygotes for T7271G and a truncating mutation. Three paternal aunts of the brothers developed breast cancer in their 50's one of whom was confirmed to be a heterozygous T7271G carrier (Stankovic et al., 1998) . Subsequently, an Australian family was reported in which five women with breast cancer were heterozygous T7271G carriers. Expression and activity analyses of ATM in cell lines from the carriers suggested that the mutation acts in a dominant negative fashion (Chenevix-Trench et al., 2002) . It is noteworthy that in our study of ATM in familial breast cancer, the only mutation that was identified more than once was T7271G, which was identified in the index case of two families that each included three first-degree relatives with breast cancer. This mutation was not detected in the 528 controls and has been shown to be very rare in several other studies (Chenevix-Trench et al., 2002; Bernstein et al., 2003; Szabo et al., 2004; Renwick et al., 2006) . These data suggest that the T72721G mutation may be associated with higher risks of breast cancer, but further studies are required to evaluate this.
Other phenotypic features in ATM heterozygotes
The original report of cancer in relatives of ataxiatelangiectasia cases suggested that cancers other than breast cancer, such as stomach, pancreas, bladder and ovarian cancer may also occur at increased frequency in ATM heterozygotes (Swift et al., 1976; Swift et al., 1991) . Subsequent studies have provided inconclusive and/or inconsistent data about whether/which additional cancers are associated with ATM heterozygosity (Geoffroy-Perez et al., 2001; Olsen et al., 2001; Thompson et al., 2005b) . Further, larger studies will be required to investigate the role of ATM in susceptibility to cancers other than breast cancer.
Whether ATM heterozygosity is associated with increased sensitivity to radiation is also unclear and has been the subject of several small studies. Radiosensitivity is a hallmark of ataxia-telangectasia cells and cells from ATM heterozygotes show intermediate sensitivity to ionizing radiation in various assays based on cell survival (Speit et al., 2000; Neubauer et al., 2002) . However, it remains unclear whether cells from ATM heterozygotes exhibit clinically relevant radiosensitivity in vivo. It has also been hypothesized that ATM heterozygotes may be over-represented in the proportion of breast cancer cases that exhibit exaggerated acute or late reaction of normal tissues following radiotherapy (Angele et al., 2003; Gutierrez-Enriquez et al., 2004; Meyer et al., 2004) . Given the increased risk of breast cancer in ATM heterozygotes the response to radiation therapy is of potential clinical importance and requires further investigation.
Clinical implementation
The demonstration that ATM mutations predispose to breast cancer could be used in risk stratification in women without cancer, to allow them to make medical and lifestyle choices to reduce their risk of breast cancer. The utility of genetic testing of breast cancer genes in reducing cancer incidence has been comprehensively demonstrated for the BRCA1 and BRCA2 genes (Domchek and Weber, 2006, this issue) . However, mutations in BRCA1 and BRCA2 confer B15-fold risks of breast cancer and >70% of women with mutations in these genes will develop the disease. By contrast, women with ATM mutations have a B2-fold risk of breast cancer and only B15% of women with such mutations will develop the disease. Currently, it is not known what determines which women with ATM mutations will develop cancer and this limits the clinical utility of identifying such mutations. However, if ATM mutations act multiplicatively or epistatically with other genetic or nongenetic breast cancer susceptibility factors it may be possible to identify women with combinations of low penetrance factors that together give risks similar to those of BRCA1/2. Such women may benefit from surveillance and surgical interventions similar to those that have proved so successful in BRCA1/2 carriers (Domchek and Weber, 2006, this issue) . ATM mutation status may also be of relevance to the treatment of breast cancer if it influences response to radiation or the efficacy of specific chemotherapies as has been suggested for BRCA-deficient tumours (Gudmundsdottir and Ashworth, 2006, this issue) .
Conclusions
After nearly 20 years of uncertainty, recent epidemiological and molecular studies have clarified the role of ATM in breast cancer and have shown that mutations that cause ataxia-telangiectasia in biallelic carriers (homozygotes) confer susceptibility to breast cancer in monoallelic carriers (heterozygotes). ATM is the fifth DNA repair gene, together with BRCA1, BRCA2, TP53 and CHEK2 shown to be involved in breast cancer predisposition. Whereas BRCA1, BRCA2 and TP53 are associated with high risks of breast cancer, ATM and CHEK2 are associated with more modest risks (Antoniou and Easton, 2006, this issue) . The reasons for this are not known and neither is it known how ATM mutations interact with other genetic or nongenetic risk factors. Future research that explicates which individuals with ATM mutations develop cancer will be crucial to the clinical translation of the now incontrovertible evidence that ATM mutations predispose to breast cancer.
